AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12890273
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy treatment for 12 weeks
Trial: 8550780
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg esterified estrogen and 2.5 mg methyltestosterone (E+A)
Trial: 8550780
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg conjugated equine estrogen (CEE)
Trial: 6619040
Drug: ticarcillin (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticarcillin (4.0 g every 6 h for 7 days)
Trial: 6619040
Drug: mezlocillin (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mezlocillin (4.0 g every 6 h for 7 days)
Trial: 6619040
Drug: placebo (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (4.0 g every 6 h for 7 days)
Trial: 27262871
Drug: Progesterone with
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone with or without hypothermia (exact dosage and duration not specified)
Trial: 20708421
Drug: 5 mg/mL
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/mL formulation of rhGH Nutropin AQ
Trial: 20708421
Drug: 2.5 mg/mL
RxNorm normalized name: iodine 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/mL formulation of rhGH Nutropin AQ
Trial: 20708421
Drug: 10 mg/mL
RxNorm normalized name: urea 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL formulation of rhGH Nutropin AQ
Trial: 17032732
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist Cetrorelix with recombinant FSH (rFSH) in group A (n = 52)
Trial: 17032732
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist Cetrorelix with rFSH in group A
Trial: 12030546
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg 17beta-estradiol (E2)
Trial: 12030546
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17beta-estradiol (E2)
Trial: 12030546
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17beta-estradiol (E2)
Trial: 1847582
Drug: Provera 20
RxNorm normalized name: Provera 200 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provera 20 mg
Trial: 1847582
Drug: Premarin 0.6
RxNorm normalized name: Premarin 0.625mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 0.6 mg
Trial: 1847582
Drug: Premarin 0.3
RxNorm normalized name: Premarin 0.3mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 0.3 mg plus Provera 10 mg
Trial: 25870994
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg once daily)
Trial: 16952918
Drug: TEA (lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEA (lidocaine 2 mg kg(‐1) followed by 3 mg kg(‐1) h(‐1) epidurally)
Trial: 6731693
Drug: Sequential pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pneumatic leg compression at pressures of 90 to 100 mm Hg
Trial: 6731693
Drug: Sequential pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pneumatic leg compression at pressures of 35 mm Hg
Trial: 6731693
Drug: Heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5,000 units three times per day
Trial: 6731693
Drug: Sequential pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pneumatic leg compression at pressures of 35 to 55 mm Hg
Trial: 26660709
Drug: Medication (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (not specified if it was part of the intervention)
Trial: 10445378
Drug: Ipsapirone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone (0.3 mg/kg body weight)
Trial: 341905
Drug: Halopredone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halopredone acetate cream (0.01%)
Trial: 30953556
Drug: iBobbly app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: iBobbly app (self-help app based on acceptance and commitment therapy)
Trial: 23630367
Drug: Injection plus
RxNorm normalized name: Bimectin Plus Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection plus exercise (n = 115)
Trial: 16479024
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (0.25 mg/day)
Trial: 14757613
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin use (> or =2 standard aspirin tablets/wk)
Trial: 14757613
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use of 0.5 to 1.5 standard tablets per week
Trial: 14757613
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use of 2 to 5 tablets per week
Trial: 14757613
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use of 6 to 14 tablets per week
Trial: 14757613
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use of more than 14 tablets per week
Trial: 14757613
Drug: Regular short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular short-term aspirin use (< or =5 years)
Trial: 14757613
Drug: Regular long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular long-term aspirin use (>5 years)
Trial: 14757613
Drug: Increasing duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing duration of aspirin use
Trial: 11511404
Drug: Amitriptyline 150
RxNorm normalized name: amitriptyline 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 150 mg
Trial: 21355143
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Fluoxetine)
Trial: 3074627
Drug: Thymic hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thymic hormone
Trial: 3074627
Drug: Pentapeptide treatment
RxNorm normalized name: pentapeptide-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentapeptide treatment
Trial: 3074627
Drug: Thymic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymic therapy
Trial: 20349684
Drug: adapalene 0.1%-benzoyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adapalene 0.1%-benzoyl peroxide 2.5% (A/BPO) fixed-dose combination gel with doxycycline hyclate 100 mg
Trial: 18490245
Drug: 8 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 Gy + zoledronic acid (4 mg iv, in 15‐min infusions)
Trial: 18490245
Drug: 6 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 Gy + zoledronic acid (4 mg iv, in 15‐min infusions)
Trial: 8604620
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin titrated to an activated partial thromboplastin time (aPTT) of 1.5 to 2.0 times control for 72 to 96 hours
Trial: 8604620
Drug: Optimal anticoagulation
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal anticoagulation (all aPTTs >60 seconds, all heparin levels>0.2 U/ml)
Trial: 8604620
Drug: Aggressive (high-intensity)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive (high-intensity) anticoagulation with heparin to achieve aPTTs >2.0 times control
Trial: 8604620
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy with heparin and aspirin
Trial: 1940267
Drug: Metoclopramide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (20 mg intravenous)
Trial: 25817849
Drug: Dexamethasone, 1
RxNorm normalized name: Dexamethasone, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 1 mg/kg, intravenous at induction of anesthesia
Trial: 16709935
Drug: Weight gain
RxNorm normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight gain of 5% or less during the first 2 months of intensive phase therapy among underweight patients
Trial: 15250174
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Durodont Zahnweiss intensiv (RDA 166) and Durodont medical fresh and white
Trial: 26874390
Drug: Beetroot Juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot Juice (BRJ) - 6.1 mmol nitrate, daily for 1 week
Trial: 26874390
Drug: Beetroot Juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot Juice (BRJ) - 6.1 mmol nitrate, single acute dose
Trial: 14730655
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 50 mcg twice daily (FP 100)
Trial: 14730655
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 125 mcg twice daily (FP 250)
Trial: 11344825
Drug: HRT (cyclical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (cyclical conjugated estrogens 0.625 mg/day plus medrogestone 5 mg/day)
Trial: 31834156
Drug: Intravaginal ovule
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal ovule containing 0.03mg estriol, treated daily for 16 weeks (Group A)
Trial: 28030601
Drug: Normal ionized
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal ionized calcium target range (1.1‐1.2 mmol/l)
Trial: 28030601
Drug: Low ionized
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low ionized calcium target range (0.95‐1.05 mmol/l)
Trial: 24411798
Drug: Perceived student
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived student drug testing
Trial: 22446569
Drug: Mobile phone
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone based monitoring (twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback)
Trial: 15226691
Drug: Cotrimoxazole prophylaxis
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole prophylaxis (one tablet per day)
Trial: 9431728
Drug: 5-sessions exposure
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-sessions exposure and cognitive restructuring (6 hr gradual treatment)
Trial: 3306379
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine administered at 3, 4, 6, and 14 months.
Trial: 28463161
Drug: PRO-CTCAE self-reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-CTCAE self-reporting during treatment
Trial: 28463161
Drug: PRO-CTCAE self-reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-CTCAE self-reporting after treatment
Trial: 24035250
Drug: Intravenous secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous secukinumab (2×10 mg/kg)
Trial: 16565959
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg dose of alcohol
Trial: 14571231
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (0.20 to 0.33 mg/kg body weight per week for 4 years)
Trial: 10910439
Drug: Essential hypertension
RxNorm normalized name: OILS,ESSENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential hypertension (no treatment)
Trial: 9010707
Drug: Matrix-type transdermal
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix-type transdermal therapeutic system (MTTS)
Trial: 9010707
Drug: Reservoir-type transdermal
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reservoir-type transdermal therapeutic system (RTTS)
Trial: 1558156
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg/100 ml in 5 min)
Trial: 1558156
Drug: Clonidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (150 micrograms/100 ml)
Trial: 23864249
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg over a 30 min infusion) every 1 month
Trial: 23864249
Drug: Clodronate (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (4 tablets per day of 1,600 mg)
Trial: 21081641
Drug: Enhanced Green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Green Prescription intervention (written exercise prescription, brief advice from a primary care nurse, face-to-face follow-up at 6 months, and 9 months of telephone support)
Trial: 21081641
Drug: Enhanced Green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Green Prescription intervention
Trial: 15503310
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan treatment
Trial: 11317685
Drug: Stainless steel
RxNorm normalized name: stainless steel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stainless steel implants
Trial: 9446435
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg on the day of operation and 3 x 25 mg orally from postoperative day 1 to 10)
Trial: 9446435
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 6 Gy radiation (administered within postoperative days 1 to 4)
Trial: 7957539
Drug: Glycopyrrolate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (1 mg i.v.)
Trial: 7957539
Drug: Captopril (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75 mg orally)
Trial: 3311818
Drug: QU.A.RT. group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QU.A.RT. group (irradiated on the operated breast with a total dose of 50 Gy plus a limited boost of 10 Gy)
Trial: 15589635
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n=103)
Trial: 9707354
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg manidipine dihydrochloride
Trial: 7880702
Drug: suxamethonium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 0.25 mg kg‐1
Trial: 2099158
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin (2 gm) and sulbactam (1 gm)
Trial: 12154207
Drug: Sulphasalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (2 g/day)
Trial: 33875
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose sodium cromoglycate (2 g/day)
Trial: 33875
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose sodium cromoglycate (160 mg/day)
Trial: 29039261
Drug: High-intensity exercise
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity exercise program (9-month, thrice-weekly, 10-minute sessions)
Trial: 19047322
Drug: Fluoxetine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (after excluding one large trial)
Trial: 17612822
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg/day) plus placebo
Trial: 17612822
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg/day) plus bupropion (50 mg/day)
Trial: 12202072
Drug: Wheeling Walks
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wheeling Walks campaign promoting 30 min of daily walking through paid media, public relations, and public health activities
Trial: 12202072
Drug: Wheeling Walks
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wheeling Walks campaign promoting 30 min of daily walking
Trial: 29036330
Drug: Experimental treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatments in multi-arm trials
Trial: 18361007
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% plus ketamine 0.5 mg/kg (group BK)
Trial: 18361007
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% plus tramadol 1 mg/kg (group BT)
Trial: 16818127
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (8 g)
Trial: 10758457
Drug: Ketamine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.1 mg kg‐1)
Trial: 10758457
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg kg‐1)
Trial: 8951191
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether (5 mg kg‐1)
Trial: 8951191
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether (5 mg kg‐1)
Trial: 8951191
Drug: Intrarectal artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal artemether (5 mg kg‐1)
Trial: 25788509
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment in PAC
Trial: 20060783
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus extended-release dipyridamole (25 mg aspirin plus 200 mg dipyridamole) twice daily within 24 hours of stroke or TIA onset.
Trial: 20060783
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus extended-release dipyridamole (100 mg aspirin) once daily after 7 days of aspirin monotherapy.
Trial: 17587504
Drug: Naltrexone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (25 mg/day) + Bupropion SR (300 mg/day)
Trial: 12079730
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (300 mg/day)
Trial: 16150793
Drug: Caffeine capsules
RxNorm normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine capsules (5 mg kg(‐1))
Trial: 16150793
Drug: High-dose adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adrenaline infusion (HAdr; adrenaline concentration, 1.2 nM)
Trial: 16150793
Drug: Low-dose adrenaline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adrenaline infusion (LAdr; adrenaline concentration, 0.75 nM)
Trial: 8889901
Drug: Tirilazad (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad (2.5 mg/kg every 3 hours for the first 12 hours, then 2.5 mg/kg every 6 hours for a total of 22 doses over 5 days)
Trial: 27609859
Drug: Allopurinol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (up to 600 mg daily)
Trial: 16630986
Drug: Oral rapamycin
RxNorm normalized name: kanamycin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rapamycin (6 mg loading dose followed by 3 mg/day for 14 days)
Trial: 15197517
Drug: Nateglinide alone
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide alone (120 mg)
Trial: 15197517
Drug: Nateglinide with
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide with sulfinpyrazone (400 mg/day for 7 days)
Trial: 11074103
Drug: Lithium (N=15),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (N=15), administered twice daily in doses varying from 1050 to 1950 mg (mean=1569 mg) for 3 weeks.
Trial: 11074103
Drug: Placebo (N=15),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (N=15), administered for 3 weeks.